Related Experiment Video
Updated: Aug 7, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Using the glucagon test to predict hypoglycemia in anorexia nervosa
D M Puddicombe1, C L Birmingham
1Eating Disorders Program, St. Paul's Hospital, Vancouver, British Columbia, Canada, V6Z 1Y6.
Eating and Weight Disorders : EWD
|July 1, 2006
Summary
The glucagon test may help predict hypoglycemia risk in anorexia nervosa (AN) patients. Further research is needed to establish normal glucagon test responses in AN.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Nutritional Psychiatry
Background:
- Hypoglycemia is an infrequent but significant complication of anorexia nervosa (AN), often emerging during refeeding.
- Established protocols for screening, treatment, and glucagon test interpretation in AN are lacking.
- The glucagon stimulation test is a potential tool for assessing hypoglycemia but has not been standardized for AN.
Purpose of the Study:
- To investigate the utility of the glucagon stimulation test in identifying hypoglycemia risk in AN patients.
- To establish a preliminary standard for the glucagon test in the context of AN.
Main Methods:
- A case series of 9 AN patients with suspected hypoglycemia was analyzed.
- The study measured blood glucose levels at baseline, 10, and 20 minutes post-intravenous glucagon injection (1.0 mg).
- A normal response was defined as a blood glucose level of 7.0 mmol/l or higher.
Main Results:
- Five out of nine patients exhibited abnormal glucagon test results.
- No significant difference in body mass index (BMI) was observed between patients with normal and abnormal test results.
- The glucagon test indicated potential hypoglycemia in a subset of the AN cohort.
Conclusions:
- The glucagon stimulation test shows promise in predicting hypoglycemia risk in AN.
- Larger studies are necessary to define the normative response to the glucagon test in AN patients.
- Standardization of the glucagon test is crucial for its clinical application in AN management.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...